Although we cannot exclude the possibility that Compound 182 might elicit direct effects in multiple immune subsets to influence tumor growth, its ability at least to repress the growth of AT3-OVA mammary tumors was attributed to the recruitment and activation of T cells, as no overt effect was evident in Rag1–/– mice that lack T cells. The gene discussed is RAG1; the disease is breast cancer.